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http://dx.doi.org/10.1016/j.kjms.201Abstract Splenic marginal zone lymphoma (SMZL) and splenic diffuse large B-cell lymphoma
(DLBCL) are the most common types of lymphomas involving the spleen. Geographic variation
in hepatitis C virus (HCV) seroprevalence is characteristic of splenic lymphomas. In Italy, HCV
seroprevalence was higher in patients with SMZL and splenic DLBCL than in patients with all
types of lymphoma. In Japan, HCV seroprevalence was higher in patients with splenic DLBCL
than in patients with all types of lymphoma; however, HCV seroprevalence in patients with
SMZL was similar to that in patients with all types of lymphoma. In this study, clinicopatholog-
ical data of 74 splenic lymphoma cases between 1988 and 2011 collected from the Department
of Pathology at National Taiwan University Hospital were analyzed. Serology for HCV infection
was available for 41 cases. Splenic DLBCL and SMZL accounted for 36% (n Z 27) and 42%
(n Z 31) of splenic lymphomas, respectively. Microscopically, most cases of DLBCL (26/27)
presented with circumscribed tumor and most cases of SMZL (28/31) presented with white pulp
expansion. HCV seroprevalence in patients with DLBCL and SMZL was 44% and 10%, respectively
(7/16 vs. 2/20, pZ 0.020). The pattern identified in this study is closer to that in Japan than in
Italy. HCV seroprevalence in patients with early-stage (I/II) and late-stage (III/IV) DLBCL was
100% and 10%, respectively (6/6 vs. 1/10, p < 0.001). Early-stage DLBCL is clinically considered
a form of primary splenic lymphoma rather than a systemic lymphoma with splenic involve-
ment. High HCV seroprevalence in patients with early-stage DLBCL suggests a role of HCV in
the pathogenesis of primary DLBCL.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.of Pathology, National Taiwan University Hospital, No. 7, Chung Shan South Road, Taipei, Taiwan.
.com (C.-W. Lin).
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Splenic lymphomas are heterogeneous. They may be
primary, arising from the spleen, or secondary, involving
the spleen as part of systemic dissemination of a lymphoma
that arises elsewhere. Primary splenic lymphoma is rare
and accounts for <1% of all lymphoma cases [1].
Splenic lymphomas may involve only the spleen (stage
I) or extend to the regional lymph nodes (LNs) (stage II).
They may also have more distant LN (stage III) or bone
marrow (BM) involvement (stage IV). Stage I lymphomas
are primary, stage II lymphomas are most often primary,
and stage III and IV lymphomas are most often
secondary.
Among splenic lymphomas, diffuse large B-cell
lymphoma (DLBCL) and splenic marginal zone lymphoma
(SMZL) are two of the most common histological types,
accounting for approximately 33% and 8% of splenic
lymphomas, respectively [2]. DLBCL of the spleen may
present in the early (I/II) or late (III/IV) stages. Biological
differences between early- and late-stage DLBCL are still
unclear. BM involvement is usually characteristic of SMZL,
but LN involvement is relatively uncommon [3].
The association between hepatitis C virus (HCV) infec-
tion and malignant lymphoma is well documented. The
prevalence rate of this association ranges from 2.8% to
19.6% [4, 5] and has been reported as 11% in Taiwan [6].
This association is due to a high infection rate in lymphomas
in extranodal sites [7], such as SMZL. For example, the
prevalence of HCV infection in patients with SMZL is 35% in
Italy [8]. Interestingly, in a Japanese series of studies, the
prevalence of HCV infection was found to be very high in
patients with splenic DLBCL (51.7%) [9]. The data suggest
that splenic DLBCL may also be associated with HCV
infection. However, data on HCV infection in splenic
lymphoma in Taiwan are limited.
In this study, clinicopathological pictures of 74 splenic
lymphomas were investigated. This is the only large series
of splenic lymphoma cases in Taiwan. In addition to
hematological factors, anti-HCV serology and associated
clinical data were reviewed. In a subgroup comparison,
early-stage splenic DLBCL was found to be highly associated
with HCV infection. Because early-stage splenic lymphomas
are considered to be primary splenic lymphomas, this




Among 2593 pathological spleen specimens in the archives
(from 1988 to 2011) of the Department of Pathology in
National Taiwan University Hospital, 97 cases had a diag-
nosis of lymphoma or hematological malignancy. Fourteen
cases of lymphoma with incomplete staging workup and
nine cases of myeloid neoplasms were excluded. Thus, 74
cases of splenic lymphoma were included in this retro-
spective study. Slides of spleen, BM, LN, and extranodal
sites were reviewed to confirm the diagnosis according to
the World Health Organization classification.Clinical data
Data concerning age at splenectomy, sex, and underlying
disease were obtained from themedical records. Laboratory
data, such as lymphocyte count in peripheral blood, serum
lactate dehydrogenase (LDH), and immunofixation electro-
phoresis of urine and serum specimens, were extracted from
the medical records. Staging workup for lymphoma included
physical examination, computed tomography (CT), and
pathological examinations of the BM and spleen.
Hepatitis-associated data, including serum anti-HCV anti-
body, HCV viral RNA, hepatitis B surface antigen (HBsAg),
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), alkaline phosphatase (ALP),g-glutamyl transpeptidase
(g-GT), total and direct bilirubin, prothrombin time (PT),
albumin, andhistoryof interferonor ribavirin treatment, liver
cirrhosis, and hepatocellular carcinoma (HCC) were
reviewed.
By the Ann Arbor staging system, splenic lymphomas
were divided into early (I/II) and late (III/IV) stages. Stage I
diseases involved only the spleen. Stage II diseases involved
the spleen and subdiaphragmatic LN. Stage III diseases
involved the spleen and LN on both sides of the diaphragm.
Stage IV diseases involved the spleen, BM, and/or other
extranodal sites.
Various treatments may follow splenectomy: oral
chemotherapy only, rituximab without intravenous chemo-
therapy, intravenous chemotherapy, or observation only.
Treatment responses, such as complete remission, partial
remission, stable disease, or progressive disease, were
evaluated by physical examination, CT, lymphocyte count,
andLDH testing, according to the criteria of the International
Working Group.
Statistical analysis
Two-sample comparisons were analyzed using Student
t test for continuous data, the Chi-square test, or Fischer’s
exact test for categorical data. Survival curves were
analyzed by the KaplaneMeier method and compared using
the log-rank test.Results
Pathological features
In the medical records evaluated in this study, 69 B-cell
lymphomas, three T-cell lymphomas, one lymphoblastic
lymphoma, and one unspecified high-grade lymphoma were
examined. SMZL and DLBCL were the most common histo-
logical types, accounting for 42% and 36% of all splenic
lymphomas, respectively. Splenectomy was rarely per-
formed in lymphomas with preferential nodal presentation,
such as Hodgkin’s lymphoma and follicular lymphoma.
Circumscribed tumors were present in 26 of the 27 cases
of DLBCL. The other case showed diffuse infiltration of the
splenic parenchyma. Typical cytology and immunopheno-
type of DLBCL was evident in all cases. In one case,
involvement of accessory spleen and hilar LN was observed,
the morphology of which was similar to that of the splenic
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involvement, paratrabecular infiltration was noted in six
and interstitial infiltration in one.
White pulp expansion was present in 28 of 31 cases of
SMZL, and three cases presented with mixed white pulp and
red pulp diseases. No expression of CD5, CD10, or cyclin D1
was observed in any case. Accessory spleen involvement
was noted in five cases of SMZL. In these cases, morphology
was nearly identical to that in the spleen. Hilar LN
involvement was observed in eight cases of SMZL. Effaced
architecture with a nodular pattern was evident in all of
these cases, and patent sinuses were noted in four of them.
Of the 26 cases with BM involvement, paratrabecular infil-
tration was evident in 15, nonparatrabecular nodular
aggregates were present in six, diffuse infiltration was
noted in two, and interstitial infiltration was noted in
three.Clinical data
In our series of 74 cases of splenic lymphoma, the average
age was 57 years and male-to-female ratio was 1.31. Details
of histology, stage, and anti-HCV status in these patients
are shown in Table 1. Note that 81% (60/74) of cases were
stage III or IV.
Among the 74 patients, data about the anti-HCV anti-
body and HBsAg were available for 41 (55%) and 40 (54%)
patients, respectively. Of the 41 patients, 11 (27%) were
tested positive for the anti-HCV antibody and five for the
serum HCV viral RNA. Of the 40 patients, 13 (33%) were
tested positive for HBsAg.
Among the 11 HCV-positive patients, the average values
of AST, ALT, ALP, and g-GT were 65 (61) U/L (reference
range: <37 U/L in males, <31 U/L in females), 65 (60) U/L
(reference range: <41 U/L in males, <31 U/L in females),
214 (96) U/L (reference range: 60e220 U/L), and 96
(83) U/L (reference range: <52 U/L), respectively. Total
and direct bilirubin, PT, and albumin levels were normal in
all patients. No patient had received interferon or ribavirin
therapy for HCV. One patient had a history of Child A liver
cirrhosis, but none had a history of HCC.Table 1 Classification of splenic lymphoma by histology, stage,
Histology Stage I Stage
Case no. HCV Case no.
Lymphoma 6 4/6 (67%) 8 3
B-cell lymphoma 5 3/5 (60%) 8 3
DLBCL 3 3/3 (100%) 7 3
SMZL 2 0/2 (0%) 0 N
CLL 0 NA 0 N
Mantle cell lymphoma 0 NA 0 N
B-cell lymphoma, NOS 0 NA 1 N
T-cell lymphoma 0 NA 0 N
Lymphoblastic lymphoma 0 NA 0 N
Lymphoma, not specified 1 1/1 (100%) 0 N
CLLZ chronic lymphocytic leukemia; DLBCLZ diffuse large B-cell lym
otherwise specified; SMZL Z splenic marginal zone lymphoma.Clinicopathological data of primary splenic
lymphomas
After exclusion of cases with BM, LN, and other extrasplenic
involvement [10], only six primary splenic lymphomas were
found, including three cases of DLBCL, two cases of SMZL,
and one unspecified high-grade lymphoma. Representative
images of these cases are shown in Fig. 1. All three cases of
primary DLBCL of the spleen were HCV positive, but two of
primary SMZL were HCV negative.
Chemotherapy was administered in two cases of DLBCL.
The other case of DLBCL received no additional therapy
after splenectomy. All three cases were disease free, with
a follow-up course of 4e119 months.
One SMZL case had stable disease for 48 months with no
additional treatment after splenectomy. In the other SMZL
case (a 43-year-old woman), mixed white pulp and red pulp
disease was evident and paraneoplastic pemphigus was
observed clinically. Despite chemotherapy, the woman died
of acute pancreatitis 10 months later.
An unusual pattern of red pulp disease accompanied by
hemophagocytosis was observed in the final case (a 37-
year-old woman) of unspecified high-grade lymphoma.
Chemotherapy was administered, but this patient died of
severe infection 8 months later.
Comparison of DLBCL and SMZL
Clinical features of DLBCL and SMZL, the two most common
types of splenic lymphoma, are compared in Table 2. HCV
seroprevalence was higher in patients with splenic DLBCL
than in those with SMZL (44% vs. 10%, p Z 0.020). In
Taiwan, HCV seroprevalence in patients with splenic DLBCL
was higher than and that in patients with SMZL was similar
to the overall HCV prevalence rate in patients with
lymphoma (11%) [6]. This finding suggests an association
between HCV infection and splenic lymphoma, particularly
splenic DLBCL.
Significant differences were observed between splenic
DLBCL and SMZL at the sites of involvement (p < 0.001). BM
involvement was higher in SMZL cases than in DLBCL casesand HCV status.
II Stage III/IV Total
HCV Case no. HCV Case no. HCV
/3 (100%) 60 4/32 (13%) 74 11/41 (27%)
/3 (100%) 56 4/31 (13%) 69 (93%) 10/39 (26%)
/3 (100%) 17 1/10 (10%) 27 (36%) 7/16 (44%)
A 29 2/18 (11%) 31 (42%) 2/20 (10%)
A 5 0/1 (0%) 5 (7%) 0/1 (0%)
A 3 1/2 (50%) 3 (4%) 1/2 (50%)
A 2 NA 3 (4%) NA
A 3 0/1 (0%) 3 (4%) 0/1 (0%)
A 1 NA 1 (1%) NA
A 0 NA 1 (1%) 1/1(100%)
phoma; HCVZ hepatitis C virus; NAZ not available; NOSZ not
Figure 1. Histology of primary splenic lymphoma: (A) three DLBCL with typical circumscribed mass, (B) occasional tumor
necrosis, and (C) large pleomorphic cells. (D) SMZL with typical white pulp expansion and biphasic appearance of white pulp
nodules. High-grade lymphoma with atypical tumor cells in the (E) red pulp and (F) hemophagocytosis. (G) SMZL with an unusual
pattern of mixed white pulp and red pulp. (H) Eosinophilic amorphous Congo red-negative material was noted. (Hematoxylineeosin
stain; original magnification: A, 40; B, 100; C, 400; D, 40; E, 200; F, 1000; G, 40; H, 40.) DLBCLZ diffuse large B-cell
lymphoma; SMZL Z splenic marginal zone lymphoma.
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was higher in SMZL cases than in DLBCL cases (37% vs. 8%,
respectively, p Z 0.016). Extranodal involvement was
observed more often in DLBCL cases than in SMZL cases
(44% vs. 10%, p Z 0.003).Different treatments were used for splenic DLBCL and
SMZL. Chemotherapy was administered in most cases of
splenic DLBCL (96%) after splenectomy. However, chemo-
therapy was administered only in approximately half (55%)
of the SMZL cases. Approximately one-third (32%) of
Table 2 Clinicopathological features of DLBCL and SMZL.
DLBCL SMZL p
Case number 27 31
Age (y) 57 62 0.250
Male/F 17:10 15:16 0.266
Site of involvement
BMþ/LNþ 5 (19%) 12 (39%) <0.001
BMþ/LNe 2 (7%) 14 (45%)
BMe/LNþ 14 (52%) 3 (10%)
BMe/LNe 6 (22%) 2 (6%)
Extranodal involvement 12 (44%) 3 (10%) 0.003
Primary splenic lymphoma 3 (11%) 2 (6%) 0.528
Accessory spleen 1 (4%) 5 (16%) 0.121
Hilar lymph node 5 (19%) 8 (26%) 0.507
Laboratory data
Lymphocytosis 2/24 (8%) 10/27 (37%) 0.016
LDH (IU/L) 1050 642 0.054
M-protein 1/4 (25%) 8/13 (62%) 0.200
Anti-HCV 7/16 (44%) 2/20 (10%) 0.020
HBsAg 3/13 (23%) 6/19 (32%) 0.599
Treatment
Observation 1 (4%) 10 (32%) 0.001
Oral chemotherapy 0 (0%) 1 (3%)
Rituximab 0 (0%) 3 (10%)
IV chemotherapy 26 (96%) 17 (55%)
Response
Complete remission 12 (44%) 7 (23%) 0.070
Partial remission 4 (15%) 3 (10%)
Stable disease 5 (19%) 16 (52%)
Progressive disease 6 (22%) 5 (16%)
2-y survival 56% 93% 0.046
M-protein was determined by serum or urine immunofixation
electrophoresis. Rituximab was administered without intrave-
nous chemotherapy.
Age Z age at splenectomy; BMþ Z bone marrow involvement;
BMe Z no bone marrow involvement; DLBCL Z diffuse large
B-cell lymphoma; HBsAg Z hepatitis B surface antigen;
HCV Z hepatitis C virus; IV Z intravenous; LDH Z lactate
dehydrogenase; LNþ Z lymph node involvement; LNe Z no
lymph node involvement; SMZL Z splenic marginal zone
lymphoma.
Table 3 Comparison of early- versus late-stage splenic
DLBCL.
Stage I/II Stage III/IV p
Case number 10 17
Age (y) 59 56 0.685
Male/female 5:5 12:5 0.285
Site of involvement
BMþ/LNþ 0 (0%) 5 (29%) 0.135
BMþ/LNe 0 (0%) 2 (12%)
BMe/LNþ 7 (70%) 7 (41%)
BMe/LNe 3 (30%) 3 (18%)
Extranodal involvement 0 (0%) 12 (71%) 0.002
Accessory spleen 0 (0%) 1 (6%) 0.435
Hilar lymph node 4 (40%) 1 (6%) 0.028
Laboratory data
Lymphocytosis 0/10 (0%) 2/14 (14%) 0.212
LDH (IU/L) 702 1317 0.124
M-protein 1/2 (50%) 0/2 (0%) 0.248
Anti-HCV 6/6 (100%) 1/10 (10%) <0.001
HBsAg 0/5 (0%) 3/8 (38%) 0.119
Treatment
Observation 1 (10%) 0 (0%) 0.184
IV chemotherapy 9 (90%) 17 (100%)
Response
Complete remission 8 (80%) 4 (24%) 0.024
Partial remission 1 (10%) 3 (18%)
Stable disease 1 (10%) 4 (24%)
Progressive disease 0 (0%) 6 (35%)
2-y survival 90% 42% 0.145
Age Z age at splenectomy; BMþ Z bone marrow involvement;
BMeZ no bone marrow involvement; DLBCLZ diffuse large B-
cell lymphoma; HBsAg Z hepatitis B surface antigen;
HCV Z hepatitis C virus; IV Z intravenous; LDH Z lactate
dehydrogenase; LNþ Z lymph node involvement; LNe Z no
lymph node involvement.
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splenectomy. Treatment response and survival rates also
differed between DLBCL and SMZL cases, but the number of
cases was too small to achieve statistical significance.
Indolent course and good survival (2-year survival: 93%)
were observed in the SMZL cases. Most patients (52%) had
stable disease without remission or progression. However,
treatment response was variable in DLBCL cases and the
2-year survival rate was only 56%.
Comparison of early- and late-stage DLBCL
To identify factors contributing to HCV infection, early- and
late-stage DLBCL cases were compared (Table 3). HCV
seroprevalence in patients with early-stage splenic DLBCL
was much higher than that in patients with late-stagesplenic DLBCL (100% vs. 10%, p < 0.001). However, HCV
seroprevalence in patients with late-stage splenic DLBCL
was similar to that in patients with SMZL (10%) and to the
overall prevalence of HCV infection in patients with
lymphoma in Taiwan (11%) [6].
Ten early-stage DLBCL cases were recorded; of these,
the status of HCV infection was known in six cases, all of
whom were HCV positive. Primary splenic lymphoma was
identified in three of these cases. Due to abdominal LN
involvement, the other three cases also presumably had
primary splenic lymphomas [10]. Therefore, the results of
this study demonstrate that HCV infection may be associ-
ated with the pathogenesis of primary DLBCL of the spleen.
For both early- and late-stage DLBCL, most cases
received chemotherapy after splenectomy (90% and 100%,
respectively). Not surprisingly, good treatment response
and better survival rates (2-year survival: 90%) were
evident in the early-stage DLBCL cases. On the other hand,
variable treatment response and lower survival rates
(2-year survival: 42%) were recorded in late-stage DLBCL
cases. For survival rate, the number of cases was too small
to achieve statistical significance.
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The country-wise prevalence of HCV infection is summa-
rized in Table 4 [4e6,8,9,11e19]. With some variation, the
prevalence of HCV infection was higher in patients with
lymphoma than in the general population of most
geographic areas. The HCV seroprevalence rate varied
widely. It accounted for approximately 35% and 10% of
patients with SMZL in Italy and in Japan, respectively [8,9].
The prevalence of splenic DLBCL varied from approximately
50% in Japan to approximately 60% in Europe [8,9,18].
Data on HCV infection in Taiwanese lymphoma patients
are limited. In a study of the association of HCV infection
and malignant lymphoma in Taiwan, Chuang et al. [6]
reported that 11% of lymphoma patients were HCV posi-
tive. In that series, two cases of SMZL were examined and
both were found to be HCV positive. No data on splenic
DLBCL in Taiwan have ever been reported. Although the
number of cases was small, one of the largest series in Asia
was investigated in this study. HCV seroprevalence in
patients with SMZL and splenic DLBCL was 10% (2/20) and
44% (7/16), respectively. This pattern is similar to thatTable 4 Seroprevalence of HCV infection.
Prevalence (%) Sample size Country Reference
General population
1.6 15,000 United States [11]
<0.5 NA Northern Europe [12]
5.2 3600 Italy [12]
1e1.9 NA Japan [13]
1.3 150 Korea [13]
5.5 23,000 Taiwan [14]
4.4 157,000 Taiwan [15]
Lymphoma
17.7 401 Italy [16]a
19.6 225 Italy [5]b
3.9 813 United States [17]c
11.3 400 Japan [18]
2.8 2679 Korea [4]
11 346 Taiwan [6]
SMZL
35 34 Italy [8]
10 10 Japan [9]
0 6 Japan [18]
100 2 Taiwan [6]
10 20 Taiwan d
Primary splenic DLBCL
47.1 21 Japan [18]
51.7 29 Japan [9]
64 14 Italy [19]
100 6 Taiwan d
DLBCL Z diffuse large B-cell lymphoma; HCV Z hepatitis C
virus; NA Z not applicable because the data are based on
a meta-analysis; SMZL Z splenic marginal zone lymphoma.
a 31% for lymphoplasmacytoid lymphoma and 27% for MZL.
b 50% for MZL and 33% for chronic lymphocytic leukemia.
c 13% for Burkitt lymphoma and 8% for MZL.
d Data of the current study.identified in a study based in Japan (SMZL: approximately
10%; splenic DLBCL: approximately 50%) but not to that
found in Italy (SMZL: approximately 35%; splenic DLBCL:
approximately 60%). Patterns of HCV infection may differ
between East Asia and Europe. Larger studies involving
more data are required to support this hypothesis.
Identification of the primary tumor site is more difficult
for lymphomas than for solid tumors. Splenic involvement is
frequently observed in late-stage lymphomas. The defini-
tion of primary splenic DLBCL is ambiguous in the litera-
ture. In this study, strict criteria were used to define
primary splenic lymphoma [1,10]. Cases with spleen
involvement only (stage I) were considered as primary
splenic lymphomas, and cases with extension to abdominal
LN (stage II) were presumed to be primary splenic
lymphomas. HCV seroprevalence in patients with early-
stage (I/II) splenic DLBCL was found to be extremely high
(6/6, 100%). HCV seroprevalence in patients with late-stage
(III/IV) splenic DLBCL (1/10, 10%) was similar to that in
patients with all types of lymphoma. This finding suggests
a role of HCV in the pathogenesis of primary splenic DLBCL.
HCV infection may cause lymphoma through several
mechanisms. In HCV infection, chronic antigen stimulation
results in lymphocyte proliferation. This proliferation may
lead to lymphoma because the immunoglobulin gene reper-
toire is similar in chronic HCV infection, cryoglobulinemia,
and HCV-associated lymphomas [20]. In addition, the HCV-
encoded E2 protein may interact with CD81 to induce B-cell
activation, reduce apoptosis, and increase double-strand
DNA break and hypermutation [21e23]. Finally, HCV may
infect lymphocytes directly [24]. Lymphoma cell lines
infected with HCV have been shown to increase cell prolif-
eration and decrease apoptotic activity [25,26].
Despite these data, the role of HCV infection in splenic
DLBCL is largely unknown. Although viral RNA and proteins
are present in splenic DLBCL [27], the immunoglobulin gene
repertoire and E2eCD81 interactions have not been char-
acterized in it.
Unlike SMZL, cases of splenic DLBCL, particularly those
in the early stages, rarely involve peripheral blood, which
makes the study of these cases difficult. First, specimens of
splenic DLBCL may be obtained by invasive procedures only.
Because of the low number of DLBCL cases and the inva-
siveness of these procedures, specimens are limited.
Second, precancerous lesions such as peripheral blood oli-
goclonal and monoclonal lymphocytosis are not character-
istic of splenic DLBCL. No stepwise model of the
pathogenesis of splenic DLBCL has been outlined. Moreover,
the benign counterpart of splenic DLBCL is not well recog-
nized histologically in the normal spleen.
Current knowledge of HCV-induced B-cell proliferation is
based on liver and peripheral blood studies [28,29]. Hep-
atosplenomegaly is a common manifestation in hematolog-
ical diseases, which suggests that liver and spleen may share
certain similarities in lymphoma cell homing. However, the
similarities or differences regarding lymphocytes and
microenvironment between these two organs are unclear. It
is questionable whether HCV induces B-cell proliferation in
the spleen in the same manner as in the liver.
Complete remission of HCV-positive SMZL after ribavirin
and interferon treatment has been reported [30]. Only two
cases of HCV-positive SMZL were evaluated in our series.
156 S.-C. Yu, C.-W. LinThe benefits of anti-HCV treatment in the clinical course of
SMZL require further evaluation.
This study is the only investigation of a large series of
splenic lymphoma patients in Taiwan. Six rare cases of
primary splenic lymphoma were reported here. The prev-
alence of HCV infection in patients with early-stage splenic
DLBCL, which were presumed to be primary in this study, is
100% in Taiwan. The prevalence pattern in Taiwan (10% for
SMZL and 44% for DLBCL) is similar to that in Japan (about
10% for SMZL and about 50% for DLBCL) but differs from that
in Italy (about 35% for SMZL and about 60% for DLBCL). The
higher HCV infection rate in DLBCL cases in Taiwan and
Japan suggests differences in the pathogenesis of splenic
lymphoma in East Asia versus Europe. The molecular
mechanism of HCV in the pathogenesis of primary DLBCL of
the spleen requires further study.
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